Boehringer Ingelheim’s (BI) adalimumab biosimilar, Cyltezo, can be successfully self-administered—via auto-injector—by most patients with rheumatoid arthritis (RA).
Boehringer Ingelheim’s adalimumab biosimilar, Cyltezo, which is approved though not yet launched in the United States and European Union, can be successfully self-administered—via auto-injector—by most patients with rheumatoid arthritis (RA).
That finding derives from a newly published paper in Expert Opinion that assessed real-life patient handling and self-injection of the biosimilar using the auto-injector device. The study, reported on by a research team led by Stanley Cohen, MD, included adult patients (aged 18 to 80 years) with moderate to severe rheumatoid arthritis (RA) at 19 sites in Poland and the United States.
The 7-week, phase 2, open-label, single-arm, interventional clinical trial in which patients self-injected 3 subcutaneous doses of the biosimilar with an auto-injector after having received training on how to use the device and having self-administered 1 training injection.
The injector device is pressed against the skin at a 90-degree angle, the user pushes an injection button confirmed by a clicking sound, and the duration of injection is approximately 10 seconds. Completion of the injection can be confirmed by inspecting the plunger in a viewer window. Injections were considered successful if the full content of the device was injected into the body.
In total, 77 patients were included in the study and completed 218 self-injections. Of those injections, 216 (99.1%) were successful as reported by both site personnel and patients. In the 2 cases of unsuccessful injections, the reported cause was that the device’s button could not be depressed by the patient. As no technical issues were identified with the device, the failure was deemed to be user error in both cases. The 2 patients with failed attempts were able to successfully administer a second injection.
The study’s authors say that, as the auto-injector presentation of the biosimilar is easy to use, there may be less unintentional nonadherence among patients receiving therapy with the biosimilar.
Reference
Cohen S, Klimiuk PA, Krahnke T, Assudani D. Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE-RL). [Published online May 15, 2018.] Expert Opinion. doi: 10.1080/17425247.2018.1472572.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.